Title: Low Pass Whole Genome sequencing - a cost-effective new technique for the identification of aneuploidies and copy number variations: a study of 1372 clinical samples in an Indian cohort

Authors: Satish Kariyaiah[1], Rashmi Rasalkar[1], Meenakshi Bhat[2], Avinash Pradhan[1], Deepika Rani Jena[1], Smitha C[1], Manjunath V[1], Lenika A[1], SriGanesh Jammula, Monisha Morris[2], Ravi Gupta[1], Eswarachari Venkataswamy[1] Sakthivel Murugan S.M.[1], Ramprasad V.L.[1] Priya Kadam[1]

Satish Kariyaiah and Rashmi Rasalkar are joint first authors

Affiliations: 1. Medgenome Labs Ltd, Bangalore, 2. Centre for Human Genetics, Bangalore

Conflict of Interest: No conflict of interest has been declared

Keywords: Low pass whole genome sequencing, copy number variations, aneuploidies, prenatal genetic testing, postnatal genetic testing

Abstract

Background: Identification and confirmation of copy number variation is an important aspect of genetic testing for several prenatal scenarios, such as abnormal maternal serum screening, abnormal ultrasound findings, high risk results on non-invasive prenatal screening as well as postnatal settings such as developmental delay, intellectual disabilities, congenital anomalies and dysmorphism as well as in couples with recurrent miscarriages. Low pass whole genome sequencing (lpWGS) followed by copy number variation (CNV) analysis has shown identification of critical pathogenic/likely pathogenic variants comprehensively with great accuracy and cost-effectiveness. We validated this technique on retrospective routine clinical samples previously assessed by an orthogonal tests, either chromosomal microarray or karyotyping or fluorescence in situ hybridization in a diagnostic laboratory and evaluated its performance.

Material and Methods: The validation included 112 clinical samples which showed the following events: 14 aneuploidies, 70 copy number variations of size range (50 kb - 116 Mb), 11 mosaics aneuplodies, 4 mosaics CNVs and 4 triploidies. These validation samples were derived from 21 fetuses (6 chorionic villus biopsies and 15 amniotic fluid samples), 25 abortuses and 66 postnatal samples. The validation was performed at two different resolutions - 1Mb and 50Kb. We then assessed the overall yield of the lpWGS assay on 1,260 clinical samples that comprised 801 fetuses, 346 products of conception/intrauterine fetal demise/stillbirth and 113 postnatal cases.

Results: We obtained 100% concordance in detecting full aneuploidies and copy number variations including mosaics and triploidy. The overall success rate of this assay that passed all quality parameters was 99.8%. (1235/1238). The overall diagnostic yield for pathogenic and likely pathogenic variants was 13.6% (168/1235), and specifically 7.3%, 28.8%, 15% for fetuses, products of conception/intrauterine fetal demise/stillbirth and post natal samples respectively. An additional 2.9% (36/1235) of overall samples showed CNVs that were classified as variants of unknown significance.

Conclusion: Overall, low pass whole genome sequencing is a sensitive and robust technique for identification of aneuploidies and copy number variations in a clinical setting.

44 **Introduction**

45 Chromosomal abnormalities in the form of aneuploidies and copy number variations (CNVs)
46 as a likely cause of a specific phenotype are important in both prenatal and postnatal
47 clinical settings Different techniques with increasing resolution and progressive
48 technological advances have been employed over the last few decades in the identification
49 of chromosome aneuploidies and CNVs. These include karyotyping which detectsCNVs with
50 resolution of approximately 5Mb or more aneuploidies, polyploidies, balanced and
51 unbalanced structural rearrangements, , and mosaicism[1], . Fluorescence in situ
52 hybridization (*FISH*)[2], Multiplex ligation probe amplification (MLPA)[3], quantitative
53 polymerase chain reaction[4] are targeted approaches for specific abnormalities.
54 Chromosome arrays such as comparative genomic hybridization and single nucleotide
55 polymorphism based array[5] have enabled analysis of a wider spectrum of abnormalities and
56 with increased resolution. Chromosomal microarray had been established as the gold
57 standard for identification of CNVs for structurally abnormal foetuses, stillbirths, products
58 of conception and for children with intellectual disability and developmental delay by
59 professional societies.[6,7] Overall, they have a proven greater yield of about 5-15% as
60 compared to karyotyping[8]. However, these array techniques are chip- based and probe
61 dependent, are expensive and have less comprehensive coverage. Emerging studies show
62 that next generation sequencing with low coverage are accurate at CNV detection, low cost
63 and with comprehensive coverage.[9,10]

64 Low-pass whole genome sequencing (lpWGS) as a method to identify aneuploidies and
65 CNVs is relatively new but the utility has been clearly demonstrated in both prenatal and
66 postnatal scenarios.[11,12,13] LpWGS refers to shallow whole genome sequencing (WGS) at a
67 lower depth, typically around 0.5X to 5X coverage, as compared to the standard depth of
68 30X to 50X in traditional WGS. This reduction in coverage significantly decreases the cost
69 and time required for analysis while still providing valuable genomic information. Although
70 CMA is currently the first-line investigation for aneuploidies and CNV identificaton, the
71 lpWGS technique developed on different NGS platforms along with sensitive CNV calling
72 algorithms provides an alternative method to detect aneuploidies and CNVs accurately[11]. An
73 increased yield with lpWGS has been demonstrated in a direct comparison between lpWGS

and chromosomal microarray in some studies.[14] Some of the advantages include lower initial input DNA compared to CMA protocols, non-probe dependency, wider coverage of genome, use of existing NGS equipment/platforms, lower costs and manpower requirements for both wet lab and data-analysis procedures, and high throughput with a shortened turnaround time.[12,13] A Chinese joint expert group in 2019 recommended the use of lpWGS as first tier diagnostic testing in pregnant women for prenatal diagnosis, especially couples with balanced chromosomal translocations, and/or with pregnancy loss.[15] Consequently, this technique is being increasingly used in clinical practice in tertiary level Chinese hospitals.[16] Recently updated guidelines by ACMG on the use of NGS techniques for the identification of structural variants state that lpWGS provides an affordable CNV detection method with a similar diagnostic yield and probable enhanced resolution than microarrays.[17]

This study was aimed at validating the lpWGS technique against a standard tests and evaluating its performance for use in detection of aneuploidies and CNVs. After the validation phase, the study aimed at evaluating the diagnostic yield in 1260 clinical samples.

Materials and Methods

Validation cohort

This validation was performed in two phases to assess the ability of lpWGS to identifying aneuploidies and CNVs. In the first phase CNVs greater than 1Mb were validated and in the second phase we assessed the sensitivity of lpWG in detecting CNVs greater than 50Kb and in triploidy identification. Samples with chromosomal mosiacism were included in both phases.

Phase I (0.5X - 0.7X): We used 85 consented retrospective clinical samples with known diagnostic results that included abberations ranging in size from 1.34 to 133 Mb. These included 15 prenatal samples (4 chorionic villus biopsies, 11 amniotic fluid), 17 products of conception and 53 postnatal samples (Figure 1). Of the total, 53 samples were previously investigated by chromosomal microarray (CMA) while 11 were investigated by karyotyping (KT), 15 by karyotyping and FISH for microdeletion syndromes, and 6 others were investigated only by FISH for specific microdeletion syndromes, particularly 22q11.2 microdeletion (Table 1). We created a panel of normal reference using 68 clinical samples with no known clinically relevant CNVs as seen on Affymetrix CytoScan™ Optima array. We evaluated these 10 mosaic samples (Table 1, mosaics), of which consisted of 7 were aneuploidy events and four CNVs with mosaic percentages ranging from 15 - 40% in phase 1 (Figure 1).

Phase II (3-5X Depth): To increase the resolution for identifying smaller CNVs (up to ~50Kb) as well as mosaicism and triploidy, which require greater sequencing depth to capture smaller variants, a total of 27 consented retrospective clincial samples were included (6 prenatal samples, 8 products of conception, and 13 postnatal samples). All these samples were previously investigated by either Affymetrix CytoScan™ Optima array, CytoScan™ 750K Array or CMA CytoScan™ XON Array and had CNVs of size range less than 1Mb and greater than 50 Kb (range 47 - 660 Kb) (Table 1, Phase II, Figure 1). To build a reference set, 42 samples without CNVs on CytoScan™ 750K Array were included.

We also included four triploidy samples, identified by MCC testing (16 STR markers/QF-PCR for aneuploidy) and CMA by a inhouse triploidy detection algorithm in phase II. We also included four mosaic aneuploidies with mosaic percentages from 30 - 65% (Table 1).

Library preparation and sequencing

DNA was extracted using both automated (QiaSymphony) and manual methods. QC-passed samples were used for whole genome library preparation at a minimum of 50ng on the Agilent Bravo platform using commercially available library prep kits. Prepared libraries were sequenced on Illumina platforms (NovaSeq 6000 or X Plus). Around 2Gb data per sample was generated in Phase I (~ 1 Mb resolution) and 15 Gb data for the samples used for ~50 Kb resolution in Phase 2. The sequencing results generated ~16 million paired-end

127 reads of 150 bp per sample, corresponding to a 0.5X - 0.7X for >1Mb size and 3X - 5X
128 coverage for >50 Kb size.

129 **Bioinformatics analysis and variant classification**

130 The raw paired-end FASTQ files were processed using Cutadapt to remove adapter
131 sequences, reads shorter than 20 bp or with a quality score below 10 phred score. CNV
132 analysis was performed using both WisecondorX and Illumina's DRAGEN v4.2. WisecondorX
133 was employed solely for validation purposes.

134 For WisecondorX analysis, the trimmed reads were aligned to the GRCh38 reference
135 genome using the Sentieon BWA aligner (sentieon-genomics-201808). Coverage at a
136 defined bin size was computed from the aligned BAM files for each sample and converted
137 into a WisecondorX compatible NPZ format. All reference NPZ files were subsequently
138 merged to create a final reference NPZ file. Segmentation was then performed based on
139 reference ploidy, grouping bins with similar ploidy levels. Segments showing ploidy
140 deviations from the reference were identified and classified as copy number variations.

141 For analysis using DRAGEN, trimmed reads were directly employed for alignment and
142 CNV detection. The reads were aligned to the GRCh38 reference genome. CNV calling was
143 performed through a comparative coverage-based approach, where coverage across
144 predefined bin sizes was calculated. Subsequently, the data underwent bias correction,
145 addressing GC-content bias, resulting in the generation of a corrected target counts file.
146 Normalization was then carried out ensuring that all reference files were also GC-corrected
147 if the sample had undergone GC bias correction. Once normalized, segmentation of the data
148 was performed based on the processed signal. This was followed by CNV detection, where
149 any segment displaying a significant deviation from the normal ploidy level—established
150 using the reference—was classified as a CNV event.

151 To identify larger events, a bin size of 200 Kb was used, with analysis performed
152 against a model based on 68 reference samples. Similarly, for identifying events larger than
153 50 Kb, a finer bin size of 20 Kb was applied, utilizing a model constructed from 42 reference
154 samples.

155 Triploidy was identified by evaluating the proportion of mutant reads in heterozygous
156 SNPs.[18] To perform this analysis, high-quality heterozygous SNPs from the 1,000 Genomes
157 Project were utilized. For each site with sufficient depth, allele frequencies were calculated
158 based on reference and alternate bases across all samples. In triploidy, the allele frequency
159 at heterozygous positions is expected to be around 0.33 or 0.66, indicating a genetic gain.
160 The variants were then categorized into three distinct groups according to their copy
161 number states: 0.33 (with a range of 0.28–0.38), 0.66 (range of 0.62–0.72), and 0.5 (range of
162 0.45–0.55). Following this, the ratio between the number of sites with 0.33 and 0.66
163 frequencies, relative to those with 0.5, was computed. Upon comparing these ratios
164 between control and positive samples, a clear distinction emerged. Samples exhibiting a
165 ratio greater than 2.4 were classified as positive for triploidy.

166 Annotation and classification of all CNVs was performed using an in-house workflow
167 developed based on the ACMG and Clinical Genome Resource (ClinGen) guidelines.

168 **Diagnostic yield of serial clinical samples by lpWGS in a clinical setting**

169 We evaluated the assay yield from 1,260 clinically consented samples (prenatal - 801,
170 POC/Intrauterine deaths/stillbirths - 346, postnatal - 113). Demographic details such as
171 maternal age, gestational age and clinical indications for testing were recorded. All prenatal
172 samples were subjected to maternal cell contamination (MCC) analysis either directly or
173 combined with aneuploidy testing through quantitative fluorescence polymerase chain
174 reaction (QF-PCR). MCC and QF-PCR analysis also identified presence of triploidy. Briefly,
175 the Devyser Compact v3 QF-PCR kit was used in accordance with the manufacturer's
176 protocol. All PCR products were genotyped using a SeqStudio Genetic Analyzer (Thermo
177 Fisher Scientific) with GeneMappe software 6 (Thermo Fisher Scientific). Only MCC negative
178 samples were processed further. These samples were evaluated after the first phase of
179 validation and therefore the CNV resolution was limited to 1Mb.

180

181 **Results**

182 We validated the data in two phases, by evaluating the performance of lpWGS 112 samples
183 to detect aneuploidies and CNVs against previous orthogonal data from CMA, karyotype
184 and FISH. Then, we analysed the performace in 1260 consecutive clinical samples.

185 **Validation results**

186 **Phase I – Identification of large CNV**

187 All aneuploidies and CNVs greater than 1Mb, identified by orthogonal tests were identified by
188 lpWGS (Table 1).

189 *lpWGS concordance with CMA* - All 13 aneuploidies and 37 CNVs identified by previous testing of 53
190 samples by chrosomsomal microarray were also identified by lpWGS (Table 1). The CNV size ranged
191 from 1.22 – 116.51 Mb. There was a high degree of concordance between the event size detected
192 by CMA and lpWGS as seen in the scatter plot (Figure 2, I). The six samples that did not show CNVs
193 on CMA did not show any CNVs on lpWGS either. To evaluate reproducibility, we re-processed 13
194 samples three times, all of which showed full concordance (Supplementary Table 1).

195 *lpWGS concordance with Karyotyping data* – Of eleven samples initially tested by karyotyping, two
196 abnormal events, one each in V10 and V18 had been identified by karyotype. LpWGS identified and
197 further characterized these two events (Table 1), first, V10, a mosaic karyotype involving derivative
198 of Y chromosome was recognized as four copies of Chromosome Y, second, V18**,** karyotype had
199 shown 46,XY,?der(15), lpWGS revealed a duplication of 25.4 Mb at 4p16.3-p15.2, identifying the
200 probable chromosomal content within the derivative chromosome. Additionally, lpWGS identified a
201 CNV, duplication of size 1.7 Mb at cytoband region 17q11.2, in sample V39, where the karyotype
202 had been reported as normal. However, this was not expected to be detected on karyotype since it
203 was below the detection limit. These three events were further confirmed by chromosomal
204 microarray (Table 1). The remaining eight samples that had not show any abnormality on karyotype
205 with a detection limit of 5Mb, did not show any CNV on lpWGS of size greater than 5Mb, either.

206 *lpWGS concordance with Karyotyping and FISH for 22q11.2 microdeletion data* – Of the sixteen
207 samples previously evaluated by both karyotyping and FISH for 22q11.2 microdeletion syndrome, 3
208 samples, V24, V17 and V31, had shown abnormalities (Table 1). LpWGS assay identified 5 CNVs
209 among these three samples. Three CNVs were seen in one sample alone (V24). This case had a
210 karyotype of 46,XY,der(5)t(5;?)(p15;?). lpWGS identified, a deletion at 5p15.33-p14.2 and
211 duplications at 8q23.2-q24.3 and 6q16.3, with sizes of 23.3 Mb, 34.3 Mb, and 2 Mb,

212 respectively. Parental karyotyping was recommended due to suspected structural variation,
213 however, no further information was available as the case was lost to follow-up. These
214 events were further confirmed by running a CMA (Table1).

215 Second, sample V17 had shown a karyotype of 46,XY,der(6) and no deletion identified by FISH
216 probe 22q11.2 deletion or for 7q deletion. However, lpWGS identified a 36.5 Mb duplication at
217 cytoband 3q25.32-q29, clarifying the chromosomal component of the derivative chromosome while
218 no variant was seen in q arm of either chromosome 7 or 22. Lastly, in V31, where karyotype had
219 identified an deletion, 46,XY,del(10)p13) and where FISH was negative for 22q11.2, lpWGS identified
220 the precise breakpoints and size, at cytoband region 10p15.3-p14 and size of 11.4Mb respectively.
221 Both findings of lpWGS were again confirmed on CMA (Table 1). In the 13 remaining samples, where
222 no event was seen by karyotyping and FISH, lpWGS also did not identify any CNV.

223 *lpWGS concordance by FISH alone* - We evaluated 5 samples by lpWGS that were previously
224 evaluated by FISH, four by FISH for 22q11.2 deletion, and one for 15q11 deletion for Angelman
225 syndrome alone, based on clinical presentation. Two samples that had shown the 22q11.2
226 microdeletion by FISH were also identified by lpWGS where microdeletions in cytoband region
227 22q11.21 of sizes 4.4 (V44) and 2.6 Mb (V45) were identified. For a sample investigated by FISH for
228 Angelman syndrome, V37, no variation was detected on chromosome 15; however, lpWGS
229 identified a 1.4 Mb deletion at 17p11.2. The events seen in V37 and V45 was also confirmed by
230 chromosomal microarray (Table 1). However V44 could not be confirmed as the sample was
231 exhausted.

232 In two samples, that did not show any deletion by FISH for 22q11.2 deletion, showed two
233 CNVs in V15, a terminal gain and loss, at cytoband region 9q32-q34.3 and 3p26.3 - p26. of size 24
234 and 4.5 Mb respectively and in the other sample, V20, one CNV, a duplication at 4q35.1-q35.2 of
235 size 2.2Mb was detected. The events in V15 and V20 were confirmed on CMA (Table 1)

236 *Concordance of mosaic events* – Of the 10 mosaic samples analyzed in Phase I, the seven
237 mosaic aneuploidies that showed mosaicism between 15% - 35% demonstrated on CMA
238 data showed concordance with lpWGS in terms of relative size and coordinates of
239 chromosomal events. Sample V51, had exhibited two distinct events—a gain and a loss on
240 the X chromosome measuring 70.4 Mb and 76.5 Mb, respectively—showed variability in
241 size when analyzed by lpWGS, with the gain measured at 41 Mb and the loss at 9.2 Mb. Of

242 the mosaic CNVs, in three samples that showed about 40% mosaicism, of size range 15.9 –
243 78.6Mb were identified by lpWGS.

244 Overall, when CMA, karyotype, and FISH results were used as the reference, lpWGS
245 demonstrated, considering at least one CNV calling algorithm, 100% sensitivity for detecting
246 CNVs previously identified, highlighting the high consistency and robust performance of this
247 NGS platform.

248 **Phase II – Identification of smaller CNVs, triploidy, mosaics**

249 Of the 27 samples analyzed in Phase 2, all variations identified by CMA were successfully
250 detected by lpWGS. The DRAGEN™ software, which demonstrated the highest
251 concordance with CMA data, was selected for subsequent analysis. The detected CNV size
252 ranged from 70 kb – 880 kb.

253 Identification of mosaic aneuploidies and CNVs In Phase 2, a different set of mosaic
254 aneuploid samples was analyzed using higher depth. The samples exhibited 30–62%
255 mosaicism, were readily identifiable by both CNV calling tools. The diverse sample set and
256 varied processing conditions allowed for an in-depth assessment of the method's accuracy
257 and consistency across multiple scenarios.

258 *Identification of Triploid*y - All four cases exhibited a significantly higher ratio compared to the
259 controls and were detectable as Triploidy. One sample was reanalyzed for reproducibility, yielding
260 fully concordant results (Figure 2h).

261 **Clinical Experience with 1260 Samples**

262 *Demographics and Indications for Testing*

263 The demographic data and diagnostic yield are summarized in Table 2, while clinical
264 indications grouped into broad categories are presented in Figure 3. For the prenatal
265 samples, the most frequent indication for invasive testing was high risk on maternal serum
266 screening (45.4%), followed by ultrasound abnormalities (36.8%). In products of conception
267 (POCs), the leading indications were spontaneous abortion, missed abortion, or intrauterine

268 death (IUD) (42%) followed by ultrasound abnormalities (33.5%). In postnatal
269 cases, dysmorphism and congenital abnormalities being the most common.

270 *Assay Success Rate and Technical Performance*

271 Result by lpWGS assay was obtained in 99.8% (1235/1238) and therefore failure rate was
272 only 0.2%. Results were obtained in all postnatal samples, with assay failure observed in
273 only three prenatal samples (1 amniotic fluid sample and 2 POCs). The call rate and
274 distribution of normal and abnormal samples by category is shown in Figure 4.

275 A total of 22 samples (21 POCs and 1 CVS) exhibited identical maternal and fetal
276 genotypes (Figure 4). No fetal genotype was identified by maternal cell contamination
277 (MCC) or quantitative fluorescence PCR (QF-PCR) which might have been caused by
278 improper sample collection. These samples were excluded from further analysis

279 *lpWGS Concordance with common aneuplodies identified by QF-PCR*

280 Of the 1260 samples, 1147 were prenatal, of which 650 were booked for rapid aneuploidy
281 screening by QF-PCR. Of these, 51/639 (7.9%) aneuploides in chromosomes 21,18,13, and
282 sex chrosomsome aneuplodies were identified by QF-PCR which were also detected by
283 lpWGS. Also in 588/639 (92%) samples where QF-PCR did not pick up any anomaly in these
284 chromosomes showed normal two copies by lpWGS as well, giving 100% concordance for
285 common aneuploidy detection. Additional aneuplodies in chromosomes 3, 14, 16, 22 were
286 identified on lpWGS. The remaning 11 samples showed identical genotype to the mother
287 indicating absence of fetal DNA in the POC tissue and were therefore exluded from further
288 testing by lpWGS.

289 *Diagnostic Yield*

290 Of the 1,235 samples with identified results (204/1235, 16.5%) 131 were aneuploidies and
291 73 significant CNVs (Table 3). Of these 37 were pathogenic/likely pathogenic copy number
292 variations (CNVs) and 36 were classified as variants of uncertain significance (VOUS). The
293 overall diagnostic yield for aneuplodies and pathogenic/likely pathogenic CNVs was 13.6%,
294 specifically, x7.3% in fetuses, 28.8% in early miscarriages, intrauterine deaths, and

295 stillbirths, 15% in postnatal cases (Table 2). Variants classified as VOUS accounted
296 for 2.9% of all samples: specifically 2.6% in prenatal cases, 2.5% in POCs/IUDs/stillbirths,
297 6.2% in postnatal cases (Supplementary Table 2).

298 Aneuploidies - Aneuploidies accounted for 78% (131/168) of abnormalities. As expected,
299 common aneuploidies involving chromosomes 21, 18, 13, X, and Y were predominantly
300 identified in: 82.7% (48/58) of fetuses and 41.9% (39/93) of POCs/IUDs/stillbirths (Figure 2a-
301 c, Table 3, Figure 5). Rare autosomal aneuploidies accounted for 32.3% (30/93) and were
302 observed exclusively in POCs. Similarly, triploidies (12.9%) were identified only in POCs, as
303 expected.

304 Pathogenic/Likely pathogenic CNVs - Smaller CNVs constituted 22% (37/168) of all cases.
305 Smaller CNVs were detected in 12.9% (12/93) of POCs/IUDs/stillbirths (Figure 5). In
306 postnatal samples, pathogenic CNVs were more common (88.2%, 15/17), while common
307 aneuploidies were observed in only 12% of cases (Figure 5).. The pathogenic CNVs ranged in
308 size from 1 Mb to 81.4 Mb. Of these: 8.3% (3/36) involved two variants per sample, while
309 the remaining cases each showed a single variant. A total of 11.9% (20/168) of variants
310 were <5 Mb, sizes that would have been missed by conventional karyotyping. One sample
311 exhibited terminal gains and losses, suggesting a balanced translocation in the parents;
312 parental testing was recommended, however this case was lost to follow-up.

313 *Identification of common microdeletion syndromes* – Multiple well known microdeletion
314 syndromes were readily identified, including: 22q11.2 deletion syndrome (T11, T32, T35),
315 Angelman/Prader-Willi syndrome (T24, T27), Williams syndrome (T8,T13,T31,T36), Cri-du-
316 chat syndrome (T30), Jacobsen syndrome (T22,T33) These findings are detailed in (Figure
317 2d-g, Table 4).

318 *Variant of uncertain significance (VOUS*) - The size of the 36 VOUS ranged from 1.05 Mb to
319 9.9 Mb (Supplementary Table S2). Parental testing was conducted in 15 parents (5 couples),
320 identifying the variant in 2 parents, resulting in an inheritance rate of 40% (2/5 couples).
321 This additional information facilitated further refinement of variant classification as well as
322 genetic counselling for the family.

323 **Discussion**

324 We present the first large study on Indian clinical samples demonstrating the clinical-grade
325 diagnostic utility of low-pass whole genome sequencing (lpWGS) for identification
326 of aneuploidies and copy number variations (CNVs) in prenatal and postnatal samples. Our
327 study achieved 100% detection rate of aneuploidies and CNVs previously detected by
328 existing gold-standard technique such as chromosomal microarray (CMA). Additionally, we
329 were able to identify CNVs below the resolution threshold of karyotyping, highlighting its
330 superior resolution. Furthermore, we also implemented a method which led to successful
331 identification of the chromosomal origin of imbalances in abnormal karyotypes, particularly
332 in cases involving derivative chromosomes.

333 The rigorous validation process was divided into two-phases. The first phase was
334 designed for detecting CNVs ≥1 Mb. Encouraged after obtaining 100% concordance we
335 increased the resolution of LOD for CNV to 50 Kb in the second phase. This approach aligns
336 with previous studies that reported reliable CNV detection at resolutions of 50–100 kb.[12, 13].
337 Importantly, our data showed no difference in resolution for CNV detection between
338 prenatal and postnatal samples, underscoring the robustness of lpWGS across diverse
339 sample types.

340 The depth of sequencing (0.5–0.7X) employed in our study was optimized for cost-
341 effectiveness and scalability while maintaining high diagnostic accuracy. At this shallow
342 sequencing depth, lpWGS effectively detected whole chromosome aneuploidies and small
343 to large structural abnormalities. Similar studies have demonstrated the reliability of lpWGS
344 at depths as low as 0.25X (Dong et al., 2017)[11], although depths below 0.5X may
345 compromise the identification of triploidy and absence of heterozygosity.[10,19] By increasing
346 the sequencing depth to 3-4X in phase two, we successfully identified triploidies using
347 a SNP-based algorithm, further enhancing the clinical utility of lpWGS.

348 Comparisons between CNV data derived from microarrays and lpWGS showed high
349 concordance in the estimated sizes of chromosome imbalances, with minor discrepancies in
350 terms of chromosomal location attributable to differences in probe spacing across
351 platforms. At a resolution of 1 Mb, our overall diagnostic yield for pathogenic/likely

352 pathogenic variants was 13.6%, comparable to the yield reported by Wang et al.[13] By
353 including VOUS, the yield increased to 16.3%, consistent with yields reported in prior
354 studies.[10,11,12] Diagnostic yields vary widely (2.83–53%) depending on sequencing depth,
355 resolution, and sample types, with the highest yields observed in POCs.

356 In line with expectations, aneuploidies were the predominant abnormalities detected
357 in fetuses (82.7%) and POC/stillbirth samples (41.9%), while smaller CNVs were more
358 prevalent in postnatal samples (88.2%). The technique reliably identified well-
359 known microdeletion syndromes, such as 22q11.2 deletion, Cri-du-chat syndrome,
360 Angelman/Prader-Willi syndrome, 1p36 deletion syndrome, and Wolf-Hirschhorn
361 syndrome.

362 We observed a VOUS rate of 2.9%, primarily in postnatal samples. It has been previously
363 suggested that lpWGS tends to detect more VOUS compared to CMA due to improved
364 resolution and uniform genome-wide coverage.[13] Previous studies have reported VOUS
365 rates ranging from 4–5.8% even by CMA. Therefore the rate observed in our study of 1260
366 samples by lpWGS was within the range reported in literature.[20] As with other genetic tests,
367 VOUS detection poses challenges for genetic counseling, particularly in prenatal settings.
368 Guidelines recommend careful interpretation with parental segregation testing, cautious
369 phenotypic correlation, and avoidance of reproductive decisions based solely on VOUS
370 findings.[21] Conversly, lpWGS may also identify novel clinically relevant CNVs that are
371 undetectable by CMA.

372 Detection of mosaicism presents another challenge in clinical diagnostics. Mosaic
373 aneuploidies are kown to occur in <1% of prenatal cases.[22] Our data showed reliable
374 mosaicism detection at levels 15%, however size variability was seen in one sample. That
375 sample probably had a complex karyotype involving chromosome X. Previous studies have
376 demonstrated mosaicism detection down to 5%.[9] Mosaicism detection accuracy remains
377 influenced by platform variability, sample quality, and maternal cell contamination. Clinical
378 interpretation of mosaicism, particularly at low levels (15–20%), requires caution, as it may
379 lead to diagnostic uncertainty and challenges in genetic counselling.[23]

380 Apart from the accuracy, our study also demonstrated that lpWGS has an extremely low
381 assay failure rate of 0.2%, significantly lower than that reported for the CMA (~4.6%).[10] This
382 low failure rate is particularly advantageous in prenatal settings, where re-sampling is often
383 impractical. Furthermore, lpWGS requires low input DNA (25–50 ng) compared to CMA (300
384 ng), making it suitable for resource-limited scenarios. Cost-effectiveness is another major
385 advantage of lpWGS assay. With lpWGS the cost of testing is reduced by 50% as compared
386 to CMA, our own calculations showed a 40-50% reduction in cost compared to low
387 resolution microarray.[10] As sequencing costs continue to decline, lpWGS is expected to
388 become increasingly accessible, particularly in low- and middle-income countries.[24]

389 One of the limitations of this study was that we did not evaluate additional rare variants
390 seen on lpWGS. Literature suggests that this technique may identify novel variants
391 undetectatble by microarrays and detected by lpWGS. Additionally, in phase two, we
392 restricted our scope to triploidies and did not analyze regions of homozygosity/uniparental
393 disomy, these are planned for subsequent phases at higher sequencing depth and
394 resolution.

395 **Conclusion**

396 In summary, lpWGS is a robust, sensitive, and scalable method for genome-wide
397 detection of aneuploidies and pathogenic CNVs. It's superior resolution, cost-effectiveness,
398 and ability to detect a wide range of abnormalities makes it an excellent alternative to CMA,
399 particularly in resource-limited clinical settings.

400 **References**

401 1. Smeets DF. Historical perspective of human cytogenetics: from microscope to
402 microarray. Clin Biochem. 2004;37:439-446.
403 2. Jia CW, Wang SY, Ma YM, Lan YL, Si YM, Yu L, Zhou LY. Fluorescence in situ
404 hybridization in uncultured amniocytes for detection of aneuploidy in 4210 prenatal
405 cases. Chin Med J (Engl). 2011;124:1164-1168.
406 3. Van Opstal D, Boter M, de Jong D, van den Berg C, Bruggenwirth HT, Wildschut HI, et
407 al. Rapid aneuploidy detection with multiplex ligation-dependent probe

408 amplification: a prospective study of 4000 amniotic fluid samples. Eur J Hum Genet.
409 2009;17:112-121.
410 4. Mann K, Hills A, Donaghue C, Thomas H, Ogilvie CM. Quantitative fluorescence PCR
411 analysis of >40,000 prenatal samples for the rapid diagnosis of trisomies 13, 18, 21
412 and monosomy X. Prenat Diagn. 2012;32:1197-1204.
413 5. Schaaf CP, Wiszniewska J, Beaudet AL. Copy number and SNP arrays in clinical
414 diagnostics. Annu Rev Genomics Hum Genet. 2011;12:25-51.
415 6. South S, Lee C, Lamb A, et al. ACMG Standards and Guidelines for constitutional
416 cytogenomic microarray analysis, including postnatal and prenatal applications:
417 revision 2013. Genet Med. 2013;15:901-909. doi:10.1038/gim.2013.129.
418 7. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al.
419 Consensus statement: Chromosomal microarray is a first-tier clinical diagnostic test
420 for individuals with developmental disabilities or congenital anomalies. Am J Hum
421 Genet. 2010;86:749-764.
422 8. Wapner RJ, Martin CL, Levy B, Ballif BC, Eng CM, Zachary JM, et al. Chromosomal
423 microarray versus karyotyping for prenatal diagnosis. N Engl J Med. 2012;367:2175-
424 2184.
425 9. Liang D, Peng Y, Lv W, Deng L, Zhang Y, Li H, et al. Copy number variation sequencing
426 for comprehensive diagnosis of chromosome disease syndromes. J Mol Diagn.
427 2014;16:519-526.
428 10. Chaubey A, Shenoy S, Mathur A, Ma Z, Valencia CA, Reddy Nallamilli BR, et al. Low-
429 pass genome sequencing: Validation and diagnostic utility from 409 clinical cases of
430 low-pass genome sequencing for the detection of copy number variants to replace
431 constitutional microarray. J Mol Diagn. 2020;22:823-840.
432 11. Dong Z, et al. Low-pass whole-genome sequencing in clinical cytogenetics: a
433 validated approach. Genet Med. 2016;18:940-948.
434 12. Wang J, Chen L, Zhou C, Wang L, Xie H, Xiao Y, et al. Prospective chromosome
435 analysis of 3429 amniocentesis samples in China using copy number variation
436 sequencing. Am J Obstet Gynecol. 2018;219(3):287.e1-287.e18.
437 doi:10.1016/j.ajog.2018.05.030.

438 13. Wang H, et al. Low-pass genome sequencing versus chromosomal microarray
439 analysis: implementation in prenatal diagnosis. Genet Med. 2020;22:500-510.
440 14. Clinical Genetics Group of Medical Genetics Branch Chinese Medical Association;
441 Professional Committee for Prenatal Diagnosis of Genetic Diseases Medical Genetics
442 Branch of Chinese Medical Association; Group of Genetic Disease Prevention and
443 Control Birth Defect Prevention and Control Committee of Chinese Society of
444 Preventive Medicine. Expert consensus on the application of low-depth whole
445 genome sequencing in prenatal diagnosis. Chin J Med Genet. 2019;36:293-296.
446 15. Zheng Y, Zhu B, Tan J, Guan Y, The Chinese Genomic Structural Variants Consortium,
447 Morton CC, et al. Experience of low-pass whole-genome sequencing-based copy
448 number variant analysis: a survey of Chinese tertiary hospitals. Diagnostics.
449 2022;12:1098. doi:10.3390/diagnostics12051098.
450 16. Raca G, Astbury C, Behlmann A, De Castro MJ, Hickey SE, Karaca E, et al. Points to
451 consider in the detection of germline structural variants using next-generation
452 sequencing: a statement of the American College of Medical Genetics and Genomics
453 (ACMG). Genet Med. 2023;25(2):100316. doi:10.1016/j.gim.2022.09.017.
454 17. Raman L, Dheedene A, De Smet M, Van Dorpe J, Menten B. WisecondorX: Improved
455 copy number detection for routine shallow whole-genome sequencing. Nucleic Acids
456 Res. 2018;47:1605-1614.
457 18. Geng Q, Cui X, Zhang Y, et al. Screening of triploid with low-coverage whole-genome
458 sequencing by a single-nucleotide polymorphism-based test in miscarriage tissue. J
459 Assist Reprod Genet. 2019;36:2525-2531. doi:10.1007/s10815-019-01588-6.
460 19. Mazzonetto PC, Villela D, da Costa SS, Krepischi ACV, Milanezi F, Migliavacca MP, et
461 al. Low-pass whole genome sequencing is a reliable and cost-effective approach for
462 copy number variant analysis in the clinical setting. Ann Hum Genet. 2024;88(2):113-
463 125. doi:10.1111/ahg.12532.
464 20. Mitrakos A, Kosma K, Makrythanasis P, Tzetis M. Prenatal chromosomal microarray
465 analysis: Does increased resolution equal increased yield? Genes. 2023;14:1519.
466 doi:10.3390/genes14081519.

467 21. Joynt ACM, Axford MM, Chad L, Costain G. Understanding genetic variants of
468 uncertain significance. Paediatr Child Health. 2021;27(1):10-11.
469 doi:10.1093/pch/pxab070.
470 22. Kang H, Wang L, Xie Y, Chen Y, Gao C, Li X, et al. Prenatal diagnosis of chromosomal
471 mosaicism in 18,369 cases of amniocentesis. Am J Perinatol. 2024;41(S 01):e2058-
472 e2068. doi:10.1055/s-0043-1770163.
473 23. Wallace SE, et al. Resources for genetics professionals — Mosaicism. In: Adam MP,
474 Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA):
475 University of Washington, Seattle; 1993-2024. Available
476 from: https://www.ncbi.nlm.nih.gov/books/NBK5854.
477 24. Srivastava S, Phadke SR. Low-pass genome sequencing: A good option for detecting
478 copy number variations. Genet Clin. 2022;15:April-June.

Table 1: List of retrospective clinical samples and its detail used for validation of lpWGS and comparison with Orthogonal test

					Orthogonal Test			Lowpass Whole genome			
Sl No.	**Sample Type**	**Age Range | Gender**	**Orthogonal Test**	**Cytoband with alteration**	**Start**	**End**	**Size (Mb)**	**Start**	**End**	**Size (Mb)**	**Concordance check**
					Phase I						
V1	POC	1st Tri	CMA	Trisomy 21	13634137	46677460	33.04	0	48129895	48.13	C
V2	CVS	-|NK	CMA	Trisomy 18	136227	80255845	80.12	0	78077248	78.08	C
V3	POC	-|NK	CMA	XXY; Trisomy 13; Trisomy 21	251880; 18862148; 13634137	156004066; 114342258; 46677460	155.75; 95.5; 33.0	518401; 18875554; 13850829	155783229; 114122514; 46484554	155.3; 95.25; 32.63	C
V4	POC	-|NK	CMA	XO; Trisomy 18	670673; 136227	156004066; 80255845	155.33; 80.1	1; 1	155270560; 80140651	155.2; 80.14	C†
V5	POC	-|NK	CMA	XO; Del:2q37.3; Dup:16p13.3p11.2	251880; 238580161; 35881	156004066; 241841231; 32836614	155.75; 3.26; 32.80	1 238530917; 1	155270560; 242032733; 31858519	155.2; 3.50; 31.86	C†
V6	POC	-|NK	CMA	XXY	2785592	155691858	152.91	1	155270560	155.2	C†
V7	POC	-|NK	CMA	XO	251880	156004066	155.75	1	155270560	155.3	C†
V8	POC	-|NK	CMA	XXX	2785592	155691858	152.91	518401	155783229	155.26	C
V9	POC	1st Tri|NK	CMA	Trisomy 12	64621	133201316	133.14	0	133851895	133.85	C
V10	DD	6-10Y|F*	KT; CMA	47,X,der(Y),der(Y)[32]/46,X,der(Y)[26]/45,X[2]; Dup Yp11.2q11.23	2782100	26277778	23.5	1	59373566	59.3	C
V11	PB	6-10 Y |M	CMA	Dup:Xq28	153063080	154164940	1.1	153029585	154403555	1.37	C
V12	AF	2nd Tri|NK	CMA	Del:Xp22.31	6568449	8188133	1.62	6567032	8126043	1.56	C
V13	PB	6-10 Y |M	CMA	Del:1p36.33p36.32	914087	4687603	3.77	1035549	4106654	3.07	C
V14	AF	2nd Tri|NK	CMA	Del:3q29	193054506	195291140	2.24	192701721	195307011	2.61	C
V15	DD	0-5 Y |M	F-22q; CMA	Negative; Del 3p26.3p26.1; Dup 9q32q34.3	20214; 114420869	4426396; 138125937	4.4; 23.7	0; 117178796	4560000; 141213431	4.5, 24	C
V16	PB	0-5 Y |M	CMA	Dup:3q13.2q13.31	112451525	115722398	3.27	112416860	115710247	3.29	C
V17	DD	0-5 Y |M	KT; F-22q, F-7q; CMA	46,XY, der(6); Negative; Negative; Dup 3q25.32q29	157312388	193491389	36.2	157001502	193501721	36.5	C
V18	DD	0-5 Y |M	KT; CMA	46, XY? der (15); Dup 4p16.3p15.2	68454	25612567	25.5	0	25640993	25.4	C
V19	PB	0-5 Y |F	CMA	Del:4q34.1q35.2	172079686	190036305	17.96	172151582	189871569	17.72	C
V20	DD	0-5 Y |NA	F-22q; CMA	Negative; Dup: 4q35.2	186249068	188459067	2.2	186981307	189181307	2.2	C
V21	PB	0-5 Y |F	CMA	Dup:4q25; Del:17p11.2	111131505; 16880332	112863326; 20488761	1.73; 3.61	111140415; 16916072	112967231; 20229100	1.83; 3.31	C
V22	PB	0-5 Y |M	CMA	Del:5q35.2q35.3	175989093	178055505	2.07	176170924	177632806	1.46	C

V23	AF	-|NK	CMA	Del:5p15.33p15.2; Dup: 20p13p12.1	113462; 80929	13788173; 15514914	13.67; 15.43	0; 0	13810000; 15360000	13.81; 15.36	C
V24	DD	0-5 Y |M	KT; F-22q; CMA	46, XY, der (5)t(5;?)(p15;?); Negative; Del 5p15.33p14.3; Dup 8q23.2q24.3; Dup 6q16.3	113462; 110872286; 100875815	23297521; 145070385; 102907265	23.2; 34.2: 2	0; 111900277; 101330543	23313813; 146364022; 10333054	23.3, 34.3, 2	C
V25	AF	-|NK	CMA	Del:6q26q27; Dup:7q33q36.3	162350656; 133640234	170610394; 159327017	8.26; 25.68	162025576; 133113445	171115067; 159138663	9.09; 26.03	C
V26	PB	0-5 Y |M	CMA	Del:7q35q36.3	145083337	159327017	14.24	145209927	159193037	13.98	C
V27	AF	-|NK	CMA	Del:7p21.3p15.2	10611592	26483627	15.87	10660000	26460000	15.80	C
V28	PB	6-10 Y |M	CMA	Dup:8q24.21q24.3; Del:21q22.3	130350392; 46045960	145070385; 46673449	14.72; 0.63	130269822	143035595	12.77	C
V29	AF	-|NK	CMA	Del:9q22.1q22.31	87988200	92870072	4.88	90521336	95971336	5.45	C
V30	AF	2nd Tri|NK	CMA	Del:10p15.3p14	100048	7701527	7.60	100048	7701527	7.60	C
V31	DD	0-5 Y |F	KT; F-22q; CMA	46, XY, del(10)(p13); Negative; Del 10p15.3p14	54087	11273168	11.2	0	11460000	11.4	C
V32	POC	-|NK	CMA	Dup:11p15.5q23.3; Del:22q11.1q11.21	230616; 16408174	116744147; 20291006	116.51; 3.88	230616; 16408174	116744147; 20291006	116.51; 3.88	C
V33	PB	0-5 Y |M	CMA	Del:13q22.2q31.3	75664252	91427209	15.76	75526376	91390174	15.86	C
V34	POC	-|NK	CMA	Del:13q32.3q34; Dup:16p13.3p13.2	101067948; 35881	114342258; 8831829	13.27; 8.79	101770197; 5260000	115169878; 8910000	13.40; 3.65	C
V35	AF	2nd Tri|NK	CMA	Del:15q13.2q13.3	30820717	32622039	1.80	30885000	32485000	1.60	C
V36	PB	0-5 Y |M	CMA	Del:15q11.2q13.1	22582283	28697883	6.12	23571052	28127176	4.56	C
V37	DD	6-10 Y |M	ANGL : CMA	Negative; Del 17p12	14196248	15601354	1.4	14000000	15500000	1.4	C
V38	AF	2nd Tri|NK	CMA	Del:17q24.1q24.2	66060439	67467739	1.41	66032271	67400943	1.37	C
V39	DD	0-5 Y |F	KT; CMA	46,XX; Dup 17q11.2	30689342	31870304	1.2	29 007057	30707057	1.7	C
V40	PB	0-5 Y |M	CMA	Del:18q21.2q21.33	54720552	62003701	7.28	54761202	61988318	7.23	C
V41	POC	-|NK	CMA	Dup:19q13.2	39151229	40281520	1.13	38942109	40426354	1.48	C
V42	PB	50-55 Y |F	CMA	Del:21q22.3	45329955	46673449	1.34	45373861	46598733	1.22	C
V43	PB	6-10 Y |M	CMA	Del:21q11.2q21.3	13644166	25925065	12.28	13850829	25933790	12.08	C
V44	DD	26-30 Y |F	F-22q	Positive	-	-	-	18862659	23270380	4.4	C
V45	DD	0-5 Y |F	F-22q; CMA	Positive; Del 22q11.21	18950000	21108369	2.2	18862659	21470380	2.6	C
V46	PB	11-15 Y |M	CMA	Del:22q13.32q13.33	48199706	50759338	2.5	48199706	50759338	2.6	C
V47	PB	0-5 Y |M	CMA	Del:3p25.3; Dup:15q11.2	8617702; 22582283	9971426; 23060000	1.35; 0.48	8392526; 22852677	10442526; 23095635	2.05; 0.24	C
V48	PB	0-5 Y |F	CMA	Del:10q22.3; Del:15q11.2q13.1	79625681; 23102621	80213053; 28458904	0.59; 5.36	79551950; 23571052	80232513; 28127176	0.68; 4.56	C
V49	POC	-|NK	CMA	Mos. Trisomy 13[0.35]	18862148	114342258	95.5	18800001	114400000	95.6	2GB

V50	PB	0-5 Y|NK	CMA	Mos. Monosomy X[0.3]	2785592	155691858	152.91	200001	156000000	155.8	2GB
V51	POC	-|NK	CMA	Mos. Dup:Xp22.31q21.1[0.4]: Mos.Del:Xq21.1q28[0.4]	8186478; 78579045	78576179; 155233098	70.39; 76.65	0; 76708058	9150000; 155270560	42.2; 78.6	2GB
V52	POC	-|NK	CMA	Mos. Monosomy 19 [0.3]	260912	58445449	58.1	200001	58600000	58.4	2GB
V53	POC	-|NK	CMA	Mos. Trisomy 8 [0.20]	208049	145070385	144.8	200001	145000000	144.8	2GB
V54	CVS	-|NK	CMA	Mos. Trisomy 13 [0.15]	18862148	114342258	95.5	18800001	114400000	95.6	2GB
V55	AF	2nd Tri|NK	CMA	Mos. Trisomy 22[0.20]	16408174	50759338	34.3	15800001	50800000	35.0	2GB
V56	CVS	2nd Tri |NK	CMA	Mos. Trisomy 20 [0.30]; Trisomy 21	81022; 13634137	64282292; 46677460	64.2; 33.04	1; 13000001	64200000; 46800000	64.2; 33.8	2GB
V57	AF	2nd Tri |NK	CMA	Mos. Dup: 1q21.1q25.2[0.36]	143459799	178083001	34.6	143200001	178200000	35.0	2GB
V58	POC	-|NK	CMA	Mos. Del: 7q11.21q21.11[0.4]	62437390	77764079	15.3	10660000	26560000	15.9	2GB
				Phase II							
V59	PB	41-45 Y |M	CMA	Dup:Xp11.22	53522223	53604372	0.08	53531129	53596588	0.07	C
V60	PB	11-15 Y |M	CMA	Hom.Del:Xp11.23p11.22	50034443	50205615	0.17	50046551	50203420	0.16	C
V61	AF	-|NK	CMA	Hom.Del:Xp21.1	31613916	31761327	0.15	31618133	31746217	0.13	C
V62	PB	0-5 Y |M	CMA	Del: 6q25.3	156987387	157101227	0.113	157010931	157094882	0.1	C
V63	PB	0-5 Y |M	CMA	Del:2p16.3	47783201	47837567	0.05	47777481	47847637	0.07	C
V64	CVS	-|NK	CMA	Del:2q31.2	178716155	178979102	0.26	178697107	178972060	0.27	C
V65	POC	-|NK	CMA	Del:16p11.2	29555976	30215609	0.66	29600001	30200000	0.59	C
V66	PB	0-5 Y |F	CMA	Del:6p25.3	1593382	1701415	0.11	1585474	1692283	0.11	C
V67	PB	0-5 Y |M	CMA	Del:9q34.3	137547852	137657680	0.11	137525141	137651995	0.13	C
V68	CVS	-|NK	CMA	Del:10p13	14944633	15022198	0.08	14945159	15033707	0.09	C
V69	PB	16-20 Y |F	CMA	Del:14q23.1	58280647	58458765	0.18	58278240	58462794	0.18	C
V70	DD	6-10 Y |M	CMA	Del:14q22.1	50553477	50726580	0.17	50561349	50720465	0.16	C
V71	AF	-|NK	CMA	Del:15q11.2	22582283	23102621	0.52	22781078	23102105	0.32	C
V72	PB	0-5 Y |M	CMA	Del:15q25.2	82536429	82583477	0.05	82547192	82615826	0.07	C
V73	DD	-|NK	CMA	Del: 6q27	170279913	170605209	0.32	170267801	170601115	0.3	C
V74	PB	0-5 Y |M	CMA	Del:16p13.3	2081121	2235560	0.15	2092639	2228021	0.14	C
V75	PB	0-5 Y |M	CMA	Dup:17q21.31	46110932	46215310	0.10	46087375	46286901	0.20	C
V76	AF	-|NK	CMA	Del:22q11.21	20704600	21110475	0.41	20725934	21092778	0.37	C
V77	PB	6-10 Y |F	CMA	Del:22q13.33	50707646	50818468	0.11	50710333	50730443	0.11	C
V78	POC	-|NK	CMA	Mos.Trisomy 16 [0.55]	35881	90088654	90.05	40001	90120000	90.1	C

V79	POC	-|NK	CMA	Mos.Trisomy 13 [0.62]	18862148	114342258	95.48	18875194	114345127	95.5	C
V80	PB	0-5 Y |F	CMA	Mos.Trisomy 9 [0.5]	203862	138125937	137.92	100001	138160000	138.1	C
V81	POC	-|NK	CMA	Mos.Monosomy 21[0.3]	13634137	46677460	33.04	12940001	46680000	33.7	C
V82	POC	-|NK	MCC	Triploidy	-	-	-	-	-	-	C
V83	POC	-|NK	MCC	Triploidy	-	-	-	-	-	-	C
V84	POC	-|NK	MCC	Triploidy	-	-	-	-	-	-	C
V85	POC	-|NK	QF-PCR	Triploidy	-	-	-	-	-	-	C

CVS – Chorionic Villous Biopsy, PB – Peripheral Blood, POC – Products of Conception, DD – Direct DNA, AF – Amniotic Fluid, 1st Tri – First Trimester, 2nd Tri – Second Trimester, NK- Not Known, CMA – Chromosomal Microarray, MCC – Maternal Cell contamination, QF-PCR – Quantitative Fluorescence – Polymerase Chain Reaction

Note: Control samples were used to build the reference model, Phase I – 68 normal samples and Phase II – 42 normal samples, other samples where no event was detected by orthogonal testing - 6 CMA, 8 karyotyping, 13 karyotyping and FISH, samples are not shown in the Table 1, C - Concordance between CMA data and lpWGS by either Wiseconder/DRAGEN CNV calling tools.

[†]DRAGEN is capable of detecting events such as segmental loss or gain through its CNV calling workflow. However, it does not directly provide information on sex chromosome anomalies. To address this, we utilized our internal workflow to compute z-scores for the X chromosome by comparing the sample against control samples. Based on these z-scores, we predict whether the sample shows signs of conditions such as XO or XXY. Samples V47 and V48 in phase I had variants below the predetermined threshold.

Table 2: Demographic data and Diagnostic yield of the 1,260 samples evaluated by lpWGS

(n=1,260)	Samples	Gestational Age / Age	Maternal Age	Normal	Abnormal	
					P/LP	VoUS
Fetus	801 (63.6%)	18W 5D (11W 1D - 33W 3D)	30.2 (17-45)	90.1% (720/799)	7.3% (58/799)	2.6% (21/799)
POC/IUD/Still birth	346 (27.5%)	18W 0D (7W 3D - 34W)	29.6 (18-47)	68.7% (222/323)	28.8% (93/323)	2.5% (8/323)
Postnatal	113 (9.0%)	16Y 2M (10D - 49Y)	-	78.8% (89/113)	15.0% (17/113)	6.2% (7/113)
Overall	-	-	**-**	**83.5% (1031/1235)**	**13.6% (168/1235)**	**2.9%(36/1235)**

Table 3: Aneuploidies and pathogenic and likely pathogenic variants identified by LP_WGS
Triploidy was identified by MCC/QF PCR data. Subsequently algorithm was optimized to identify the Triploidy by increasing the depth of sequencing in validation phase II.

Nomenclature	Overall (n=168)	Fetus (n=58)	POC/IUD/Still birth (n=93)	Postnatal (n=17)
Common Aneuploidies				
Trisomy 21	38 (22.6%)	28 (48.3%)	8 (8.6%)	2 (11.8%)
Trisomy 18	16 (9.5%)	11 (19.0%)	5 (5.4%)	-
Trisomy 13	6 (3.6%)	3 (5.2%)	3 (3.2%)	-
Sex Chromosome Aberrations				
Turner syndrome	19 (11.3%)	1 (1.7%)	18 (19.4%)	-
Triple X syndrome	2 (1.2%)	2 (3.4%)	-	-
Klinefelter syndrome	2 (1.2%)	2 (3.4%)	-	-
Jacob's syndrome	2 (1.2%)	1 (1.7%)	1 (1.1%)	-
Others	3 (1.8%)	-	3 (3.2%)	-
Rare Autosomes Aberrations				
Trisomy 3	2 (1.2%)	-	2 (2.2%)	-
Trisomy 7	2 (1.2%)	-	2 (2.2%)	-
Trisomy 8	2 (1.2%)	-	2 (2.2%)	-
Trisomy 10	2 (1.2%)	-	2 (2.2%)	-
Trisomy 14	3 (1.8%)	-	3 (3.2%)	-
Trisomy 15	2 (1.2%)	-	2 (2.2%)	-
Trisomy 16	9 (5.4%)	-	9 (9.7%)	-
Trisomy 17	1 (0.6%)	-	1 (1.1%)	-
Trisomy 22	7 (4.2%)	-	7 (7.5%)	-
Other combinations				
Klinefelter syndrome +Trisomy 18	1 (0.6%)	-	1 (1.1%)	-
Triploidy	12 (7.1%)	-	12 (12.9%)	-
Aneuploidy (Including Triploidy)	131 (78.0%)	48 (82.8%)	81 (87.1%)	2 (11.8%)
Copy number variations (Pathogenic/Likely pathogenic)	37 (22.0%)	10 (17.2%)	12 (12.9%)	15 (88.2%)
<5Mb size	20 (20/1235,1.6%) (20/168,11.9%)	7 (7/1235,0.6%) (7/58, 12.1%)	6 (6/1235,0.5%) (6/93,6.5%)	7 (7/1235,0.6%) (7/17,41.2%)
>5 Mb size	17 (17/1235,1.4%)	3 (3/1235,0.2%)	6 (6/1235,0.5%)	8 (8/1235,0.6%)

Table 4: Summary of the smaller pathogenic copy number variation identified by the low pass whole genome sequencing.
1st Tri – First Trimester, 2nd Trimester – Second Trimester

Sl No.	Sample Type	Age Range	Cytoband	Size (Mb)	Associated Syndrome
T1	Amniotic Fluid	1st Trimester	Del:17p12	1.50	Charcot-Marie-Tooth Disease Type 1A (CMT1A)
T2	Amniotic Fluid	-	Del:17q11.2	2.60	-
T3	Amniotic Fluid	2nd Trimester	Del:7q31.33-q33	10.50	-
T4	Amniotic Fluid	2nd Trimester	Del:17q12	1.75	Renal Cysts and Diabetes Syndrome (RCAD)
T5	Chorionic Villus Sample	1st Trimester	Mos.Del: Xq24	2.45	-
T6	Chorionic Villus Sample	-	Del:16p12.2-p11.2	8.00	Rubinstein-Taybi Syndrome
T7	Amniotic Fluid	2nd Trimester	Del: Xp22.31	1.85	Ichthyosis, X-linked (Steroid Sulfatase Deficiency)
T8	Amniotic Fluid	-	Mos.Del: 7q11.22-q11.23	3.75	Williams Syndrome
T9	Chorionic Villus Sample	2nd Trimester	Mos.Del: 13q32.3–q33.1	1.50	-
T10	Amniotic Fluid	2nd Trimester	Del: 12q21.1-q21.33	15.60	Noonan Syndrome (PTPN11 gene)
T11	Product of conception	-	Del: 22q11.21	1.41	DiGeorge Syndrome/Velocardiofacial Syndrome
T12	Product of conception	-	Del: 15q26.2-q26.3	7.80	-
T13	Product of conception	-	Del: 7q11.21-q11.23	13.96	Williams Syndrome
T14	Product of conception	-	Mos. Dup: 5q23.1-q23.3	14.00	Crohn's Disease (NOD2 gene)
T15	Product of conception	-	Del:8p23.3-p11.1, Mos.Dup:8q12.3 - q24.3	45.14,81.4	Langer-Giedion Syndrome; Burkitt Lymphoma
T16	Product of conception	1st Trimester	Del: 2q36.1-q36.3, Del: 11q22.3 - q23.1	6.2,1	Potocki-Shaffer Syndrome
T17	Product of conception	-	Del: 6p24.3-p23, Del: 7q31.32 - q31.33	5.8,1.3	Cornelia de Lange Syndrome
T18	Product of conception	-	Del: 2q37.2-q37.3	6.95	-
T19	Product of conception	-	Del: 14q12	1.60	-

T20	Product of conception	-	Del:1q21.1-q21.2	1.80	TAR Syndrome
T21	Product of conception	-	Dup: 17p12	1.40	-
T22	Peripheral Blood	0-5Y	Del: 11q23.3-q25	14.06	Jacobsen Syndrome
T23	Peripheral Blood	0-5 Y	Del: 11q23.3-q25	14.06	Jacobsen Syndrome
T24	Peripheral Blood	0-5 Y	Del: 15q11.2-q13.1	5.00	Prader-Willi Syndrome, Angelman Syndrome
T25	Peripheral Blood	26-30 Y	Del: 10q21.1	1.90	-
T26	Peripheral Blood	0-5 Y	Del: 1p32.1-p31.3	3.10	-
T27	Peripheral Blood	16-20 Y	Dup: 15q11.2-q13.1	7.29	Prader-Willi Syndrome, Angelman Syndrome
T28	Peripheral Blood	0-5 Y	Del: 10q11.22-q11.23	5.90	-
T29	Peripheral Blood	0-5 Y	Dup: 12p13.33-p13.31, Dup: 6q15	9.66,1.3	-
T30	Peripheral Blood	6-10 Y	Del: 5p15.33-p14.1	25.41	Cri-du-Chat Syndrome
T31	Peripheral Blood	6-10 Y	Del: 7q11.23	2.65	Williams Syndrome
T32	Peripheral Blood	6-10 Y	Del: 22q11.21	1.30	DiGeorge Syndrome, Velocardiofacial Syndrome
T33	Peripheral Blood	0-5 Y	Dup: 7p22.3-p21.3	8.36	Greig Cephalopolysyndactyly Syndrome
T34	Peripheral Blood	26-30 Y	Dup: 9p24.3-p13.1	38.71	Alagille Syndrome (JAG1 gene)
T35	Peripheral Blood	0-5 Y	Del: 22q11.21	2.20	DiGeorge Syndrome, Velocardiofacial Syndrome
T36	Peripheral Blood	0-5 Y	Del: 7q11.23	1.60	Williams syndrome
T37	Product of conception	-	Dup:13q31.3-q34, Del: 18q21.33 - q23	24.7;17.96	-



Figure 01: Validation flow chart divided in Phase 1 and Phase II



Figure 02: Commonly occurring Aneuploidies and events Trisomy 21(a) Trisomy 18 (b), XO/Turner syndrome (c), 7q11.23 del / Williams Beuren Syndrome (d), 15q11.2q13.1 del / Prader-Willi/Angelman Syndrome (e), 22q11.21 del / DiGeorge Syndrome (f), 5p15.33p13.3 del / Cri du Chat syndrome (g), Triploidy (h), scatterplot CMA vs lpWGS (i)



Figure 03: Distribution of Clinical indications of 1260 samples **A**. Fetus, **B**. POC, **C**. Postnatal



*Overall call rate is 99.8% (1235/1238), Failure rate 0.2%(3/1238) Abnormal (P/LP/VoUS)

Figure 04: Diagnostic yield for lowpass whole genome sequencing of 1260 samples.



Figure 05: Aneuploidies and pathogenic and likely pathogenic variants identified by lpWGS